메뉴 건너뛰기




Volumn 8, Issue 3, 2016, Pages

Targeted therapy in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (LA-R/M HNSCC)

Author keywords

Cetuximab; EGFR; HNSCC; SCCHN; Signal transduction

Indexed keywords

AFATINIB; BEVACIZUMAB; BUPARLISIB; CETUXIMAB; DACOMITINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIMOTUZUMAB; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SONOLISIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ZALUTUMUMAB;

EID: 84959354273     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8030027     Document Type: Review
Times cited : (40)

References (106)
  • 2
    • 0034651902 scopus 로고    scopus 로고
    • Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck
    • Adelstein, D.J.; Lavertu, P.; Saxton, J.P.; Secic, M.; Wood, B.G.; Wanamaker, J.R.; Eliachar, I.; Strome, M.; Larto, M.A. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88, 876–883.
    • (2000) Cancer , vol.88 , pp. 876-883
    • Adelstein, D.J.1    Lavertu, P.2    Saxton, J.P.3    Secic, M.4    Wood, B.G.5    Wanamaker, J.R.6    Eliachar, I.7    Strome, M.8    Larto, M.A.9
  • 3
    • 0027254069 scopus 로고
    • How many mutations are required for tumorigenesis? Implications from human cancer data
    • Renan, M.J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 1993, 7, 139–146.
    • (1993) Mol. Carcinog , vol.7 , pp. 139-146
    • Renan, M.J.1
  • 5
    • 84923197605 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of head and neck squamous cell carcinomas
    • Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517, 576–582.
    • (2015) Nature , vol.517 , pp. 576-582
  • 6
    • 0033542145 scopus 로고    scopus 로고
    • Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma
    • Okami, K.; Reed, A.L.; Cairns, P.; Koch, W.M.; Westra, W.H.; Wehage, S.; Jen, J.; Sidransky, D. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999, 18, 3541–3545.
    • (1999) Oncogene , vol.18 , pp. 3541-3545
    • Okami, K.1    Reed, A.L.2    Cairns, P.3    Koch, W.M.4    Westra, W.H.5    Wehage, S.6    Jen, J.7    Sidransky, D.8
  • 7
    • 84929505977 scopus 로고    scopus 로고
    • Molecular biology and immunology of head and neck cancer
    • Guo, T.; Califano, J.A. Molecular biology and immunology of head and neck cancer. Surg. Oncol. Clin. N. Am. 2015, 24, 397–407.
    • (2015) Surg. Oncol. Clin. N. Am , vol.24 , pp. 397-407
    • Guo, T.1    Califano, J.A.2
  • 10
  • 11
    • 0034833599 scopus 로고    scopus 로고
    • Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions
    • Nagatsuka, H.; Ishiwari, Y.; Tsujigiwa, H.; Nakano, K.; Nagai, N. Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol. 2001, 37, 599–604.
    • (2001) Oral Oncol , vol.37 , pp. 599-604
    • Nagatsuka, H.1    Ishiwari, Y.2    Tsujigiwa, H.3    Nakano, K.4    Nagai, N.5
  • 12
    • 0036286452 scopus 로고    scopus 로고
    • Mutant epidermal growth factor receptors as targets for cancer therapy
    • Lorimer, I.A. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr. Cancer Drug Targets 2002,2, 91–102.
    • (2002) Curr. Cancer Drug Targets , vol.2 , pp. 91-102
    • Lorimer, I.A.1
  • 13
    • 0001744237 scopus 로고    scopus 로고
    • Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines
    • Rubin Grandis, J.; Zeng, Q.; Tweardy, D.J. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat. Med. 1996, 2, 237–240.
    • (1996) Nat. Med , vol.2 , pp. 237-240
    • Rubin Grandis, J.1    Zeng, Q.2    Tweardy, D.J.3
  • 14
    • 0033227225 scopus 로고    scopus 로고
    • Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage
    • Chen, B.K.; Ohtsuki, Y.; Furihata, M.; Takeuchi, T.; Iwata, J.; Liang, S.B.; Sonobe, H. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int. J. Oncol. 1999, 15, 893–898.
    • (1999) Int. J. Oncol , vol.15 , pp. 893-898
    • Chen, B.K.1    Ohtsuki, Y.2    Furihata, M.3    Takeuchi, T.4    Iwata, J.5    Liang, S.B.6    Sonobe, H.7
  • 15
    • 0037115674 scopus 로고    scopus 로고
    • Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
    • Ang, K.K.; Berkey, B.A.; Tu, X.; Zhang, H.Z.; Katz, R.; Hammond, E.H.; Fu, K.K.; Milas, L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62, 7350–7356.
    • (2002) Cancer Res , vol.62 , pp. 7350-7356
    • Ang, K.K.1    Berkey, B.A.2    Tu, X.3    Zhang, H.Z.4    Katz, R.5    Hammond, E.H.6    Fu, K.K.7    Milas, L.8
  • 17
    • 0036076482 scopus 로고    scopus 로고
    • Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features
    • Rodrigo, J.P.; Gonzalez, M.V.; Lazo, P.S.; Ramos, S.; Coto, E.; Alvarez, I.; Garcia, L.A.; Suarez, C. Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features. Oral Oncol. 2002, 38, 357–363.
    • (2002) Oral Oncol , vol.38 , pp. 357-363
    • Rodrigo, J.P.1    Gonzalez, M.V.2    Lazo, P.S.3    Ramos, S.4    Coto, E.5    Alvarez, I.6    Garcia, L.A.7    Suarez, C.8
  • 18
    • 0034919864 scopus 로고    scopus 로고
    • Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
    • Crombet, T.; Torres, O.; Rodriguez, V.; Menendez, A.; Stevenson, A.; Ramos, M.; Torres, F.; Figueredo, R.; Veitia, I.; Iznaga, N.; et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study. Hybridoma 2001, 20, 131–136.
    • (2001) Hybridoma , vol.20 , pp. 131-136
    • Crombet, T.1    Torres, O.2    Rodriguez, V.3    Menendez, A.4    Stevenson, A.5    Ramos, M.6    Torres, F.7    Figueredo, R.8    Veitia, I.9    Iznaga, N.10
  • 20
    • 0028819660 scopus 로고
    • Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
    • Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1, 1311–1318.
    • (1995) Clin. Cancer Res , vol.1 , pp. 1311-1318
    • Goldstein, N.I.1    Prewett, M.2    Zuklys, K.3    Rockwell, P.4    Mendelsohn, J.5
  • 21
    • 0029670014 scopus 로고    scopus 로고
    • Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
    • Wu, X.; Rubin, M.; Fan, Z.; DeBlasio, T.; Soos, T.; Koff, A.; Mendelsohn, J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12, 1397–1403.
    • (1996) Oncogene , vol.12 , pp. 1397-1403
    • Wu, X.1    Rubin, M.2    Fan, Z.3    Deblasio, T.4    Soos, T.5    Koff, A.6    Mendelsohn, J.7
  • 22
    • 0035398021 scopus 로고    scopus 로고
    • Phase I study of anti—Epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
    • Robert, F.; Ezekiel, M.P.; Spencer, S.A.; Meredith, R.F.; Bonner, J.A.; Khazaeli, M.B.; Saleh, M.N.; Carey, D.; LoBulio, A.F.; Wheeler, R.H.; et al. Phase I study of anti—Epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 3234–3243.
    • (2001) J. Clin. Oncol , vol.19 , pp. 3234-3243
    • Robert, F.1    Ezekiel, M.P.2    Spencer, S.A.3    Meredith, R.F.4    Bonner, J.A.5    Khazaeli, M.B.6    Saleh, M.N.7    Carey, D.8    Lobulio, A.F.9    Wheeler, R.H.10
  • 25
    • 0033561522 scopus 로고    scopus 로고
    • Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
    • Huang, S.M.; Bock, J.M.; Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59, 1935–1940.
    • (1999) Cancer Res , vol.59 , pp. 1935-1940
    • Huang, S.M.1    Bock, J.M.2    Harari, P.M.3
  • 26
    • 33644971314 scopus 로고    scopus 로고
    • Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm
    • Pfister, D.G.; Su, Y.B.; Kraus, D.H.; Wolden, S.L.; Lis, E.; Aliff, T.B.; Zahalsky, A.J.; Lake, S.; Needle, M.N.; Shaha, A.R.;et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 2006, 24, 1072–1078.
    • (2006) J. Clin. Oncol , vol.24 , pp. 1072-1078
    • Pfister, D.G.1    Su, Y.B.2    Kraus, D.H.3    Wolden, S.L.4    Lis, E.5    Aliff, T.B.6    Zahalsky, A.J.7    Lake, S.8    Needle, M.N.9    Shaha, A.R.10
  • 28
    • 0026645077 scopus 로고
    • Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs.Methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
    • Forastiere, A.A.; Metch, B.; Schuller, D.E.; Ensley, J.F.; Hutchins, L.F.; Triozzi, P.; Kish, J.A.; McClure, S.; VonFeldt, E.; Williamson, S.K. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs.methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J. Clin. Oncol. 1992, 10, 1245–1251.
    • (1992) J. Clin. Oncol , vol.10 , pp. 1245-1251
    • Forastiere, A.A.1    Metch, B.2    Schuller, D.E.3    Ensley, J.F.4    Hutchins, L.F.5    Triozzi, P.6    Kish, J.A.7    McClure, S.8    Vonfeldt, E.9    Williamson, S.K.10
  • 29
    • 23744495620 scopus 로고    scopus 로고
    • A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy
    • Leon, X.; Hitt, R.; Constenla, M.; Rocca, A.; Stupp, R.; Kovacs, A.F.; Amellal, N.; Bessa, E.H.; Bourhis, J. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 2005, 17, 418–424.
    • (2005) Clin. Oncol. (R. Coll. Radiol.) , vol.17 , pp. 418-424
    • Leon, X.1    Hitt, R.2    Constenla, M.3    Rocca, A.4    Stupp, R.5    Kovacs, A.F.6    Amellal, N.7    Bessa, E.H.8    Bourhis, J.9
  • 30
    • 23844523253 scopus 로고    scopus 로고
    • Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
    • Baselga, J.; Trigo, J.M.; Bourhis, J.; Tortochaux, J.; Cortes-Funes, H.; Hitt, R.; Gascon, P.; Amellal, N.; Harstrick, A.; Echkardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 5568–5577.
    • (2005) J. Clin. Oncol , vol.23 , pp. 5568-5577
    • Baselga, J.1    Trigo, J.M.2    Bourhis, J.3    Tortochaux, J.4    Cortes-Funes, H.5    Hitt, R.6    Gascon, P.7    Amellal, N.8    Harstrick, A.9    Echkardt, A.10
  • 31
    • 24944490558 scopus 로고    scopus 로고
    • Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
    • Herbst, R.S.; Arquette, M.; Shin, D.M.; Dicke, K.; Vokes, E.E.; Azarnia, N.; Hong, W.K.; Kies, M.S. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 5578–5587.
    • (2005) J. Clin. Oncol , vol.23 , pp. 5578-5587
    • Herbst, R.S.1    Arquette, M.2    Shin, D.M.3    Dicke, K.4    Vokes, E.E.5    Azarnia, N.6    Hong, W.K.7    Kies, M.S.8
  • 32
    • 33144461661 scopus 로고    scopus 로고
    • Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study
    • Burtness, B.; Goldwasser, M.A.; Flood, W.; Mattar, B.; Forastiere, A.A.; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005, 23, 8646–8654.
    • (2005) J. Clin. Oncol , vol.23 , pp. 8646-8654
    • Burtness, B.1    Goldwasser, M.A.2    Flood, W.3    Mattar, B.4    Forastiere, A.A.5
  • 34
    • 84859483100 scopus 로고    scopus 로고
    • Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    • Hitt, R.; Irigoyen, A.; Cortes-Funes, H.; Grau, J.J.; Garcia-Saenz, J.A.; Cruz-Hernandez, J.J.; Spanish Head and Neck Cancer Cooperative Groupo (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann. Oncol. 2012, 23, 1016–1022.
    • (2012) Ann. Oncol , vol.23 , pp. 1016-1022
    • Hitt, R.1    Irigoyen, A.2    Cortes-Funes, H.3    Grau, J.J.4    Garcia-Saenz, J.A.5    Cruz-Hernandez, J.J.6
  • 35
    • 84859813676 scopus 로고    scopus 로고
    • New promising molecular targets in head and neck squamous cell carcinoma
    • Bauman, J.E.; Michel, L.S.; Chung, C.H. New promising molecular targets in head and neck squamous cell carcinoma.Curr. Opin. Oncol. 2012, 24, 235–242.
    • (2012) Curr. Opin. Oncol , vol.24 , pp. 235-242
    • Bauman, J.E.1    Michel, L.S.2    Chung, C.H.3
  • 36
    • 84874107117 scopus 로고    scopus 로고
    • Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
    • Shin, D.M.; Khuri, F.R. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2013, 35, 443–453.
    • (2013) Head Neck , vol.35 , pp. 443-453
    • Shin, D.M.1    Khuri, F.R.2
  • 37
    • 84903194826 scopus 로고    scopus 로고
    • Novel treatments for head and neck squamous cell carcinoma: Preclinical identification and clinical investigation
    • Bowles, D.W.; McDermott, J.D.; Jimeno, A. Novel treatments for head and neck squamous cell carcinoma: Preclinical identification and clinical investigation. Future Oncol. 2014, 10, 1065–1080.
    • (2014) Future Oncol , vol.10 , pp. 1065-1080
    • Bowles, D.W.1    McDermott, J.D.2    Jimeno, A.3
  • 38
    • 84896696623 scopus 로고    scopus 로고
    • Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
    • Cohen, R.B. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat. Rev. 2014,40, 567–577.
    • (2014) Cancer Treat. Rev , vol.40 , pp. 567-577
    • Cohen, R.B.1
  • 39
    • 84879785532 scopus 로고    scopus 로고
    • Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial
    • Vermorken, J.B.; Stohlmacher-Williams, J.; Davidenko, I.; Licitra, L.; Winquist, E.; Villanueva, C.; Foa, P.; Rottey, S.; Skladowski, K.; Tahara, M.; et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial.Lancet Oncol. 2013, 14, 697–710.
    • (2013) Lancet Oncol , vol.14 , pp. 697-710
    • Vermorken, J.B.1    Stohlmacher-Williams, J.2    Davidenko, I.3    Licitra, L.4    Winquist, E.5    Villanueva, C.6    Foa, P.7    Rottey, S.8    Skladowski, K.M.9
  • 40
    • 79953183347 scopus 로고    scopus 로고
    • Zalutumumab plus best supportive care vs. Best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised phase 3 trial
    • Machiels, J.P.; Subramanian, S.; Ruzsa, A.; Repassy, G.; Lifirenko, I.; Flygare, A.; Sorensen, P.; Nielsen, T.; Lisby, S.; Clement, P.M. Zalutumumab plus best supportive care vs. best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised phase 3 trial. Lancet Oncol. 2011, 12, 333–343.
    • (2011) Lancet Oncol , vol.12 , pp. 333-343
    • Machiels, J.P.1    Subramanian, S.2    Ruzsa, A.3    Repassy, G.4    Lifirenko, I.5    Flygare, A.6    Sorensen, P.7    Nielsen, T.8    Lisby, S.9    Clement, P.M.10
  • 42
    • 84876073132 scopus 로고    scopus 로고
    • Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An eastern cooperative oncology group trial
    • Argiris, A.; Ghebremichael, M.; Gilbert, J.; Lee, J.W.; Sachidanandam, K.; Kolesar, J.M.; Burtness, B.; Forastiere, A.A. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An eastern cooperative oncology group trial. J. Clin. Oncol. 2013, 31, 1405–1414.
    • (2013) J. Clin. Oncol , vol.31 , pp. 1405-1414
    • Argiris, A.1    Ghebremichael, M.2    Gilbert, J.3    Lee, J.W.4    Sachidanandam, K.5    Kolesar, J.M.6    Burtness, B.7    Forastiere, A.A.8
  • 43
    • 1842772526 scopus 로고    scopus 로고
    • Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
    • Soulieres, D.; Senzer, N.N.; Vokes, E.E.; Hidalgo, M.; Agarwala, S.S.; Siu, L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004, 22, 77–85.
    • (2004) J. Clin. Oncol , vol.22 , pp. 77-85
    • Soulieres, D.1    Senzer, N.N.2    Vokes, E.E.3    Hidalgo, M.4    Agarwala, S.S.5    Siu, L.L.6
  • 44
    • 34250208469 scopus 로고    scopus 로고
    • Phase I/II trial of Erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    • Siu, L.L.; Soulieres, D.; Chen, E.X.; Pond, G.R.; Chin, S.F.; Francis, P.; Harvey, L.; Klein, M.; Zhang, W.; Dancey, J.; et al. Phase I/II trial of Erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2007, 25, 2178–2183.
    • (2007) J. Clin. Oncol , vol.25 , pp. 2178-2183
    • Siu, L.L.1    Soulieres, D.2    Chen, E.X.3    Pond, G.R.4    Chin, S.F.5    Francis, P.6    Harvey, L.7    Klein, M.8    Zhang, W.J.9
  • 46
    • 84903764970 scopus 로고    scopus 로고
    • A randomized, phase II study of afatinib vs. Cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
    • Seiwert, T.Y.; Fayette, J.; Cupissol, D.; Del Campo, J.M.; Clement, P.M.; Hitt, R.; Degardin, M.; Zhang, W.; Blackman, A.; Ehrnrooth, E.; et al. A randomized, phase II study of afatinib vs. cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol. 2014, 25, 1813–1820.
    • (2014) Ann. Oncol , vol.25 , pp. 1813-1820
    • Seiwert, T.Y.1    Fayette, J.2    Cupissol, D.3    Del Campo, J.M.4    Clement, P.M.5    Hitt, R.6    Degardin, M.7    Zhang, W.8    Blackman, A.E.9
  • 47
    • 84903244134 scopus 로고    scopus 로고
    • Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib vs. Methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
    • Machiels, J.P.; Licitra, L.F.; Haddad, R.I.; Tahara, M.; Cohen, E.E. Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib vs. methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer 2014, 14, 473.
    • (2014) BMC Cancer , vol.14
    • Machiels, J.P.1    Licitra, L.F.2    Haddad, R.I.3    Tahara, M.4    Cohen, E.E.5
  • 48
    • 84933678811 scopus 로고    scopus 로고
    • Afatinib vs. Methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial
    • Machiels, J.P.; Haddad, R.I.; Fayette, J.; Licitra, L.F.; Tahara, M.; Vermorken, J.B.; Clement, P.M.; Gauler, T.; Cupissol, D.; Grau, J.J.; et al. Afatinib vs. methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. Lancet Oncol. 2015, 16, 583–594.
    • (2015) Lancet Oncol , vol.16 , pp. 583-594
    • Machiels, J.P.1    Haddad, R.I.2    Fayette, J.3    Licitra, L.F.4    Tahara, M.5    Vermorken, J.B.6    Clement, P.M.7    Gauler, T.8    Cupissol, D.J.J.9
  • 49
    • 84874569165 scopus 로고    scopus 로고
    • A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
    • Abdul Razak, A.R.; Soulieres, D.; Laurie, S.A.; Hotte, S.J.; Singh, S.; Winquist, E.; Chia, S.; LeTourneau, C.; Nguyen-Tan, P.F.; Chen, E.X.; et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann. Oncol. 2013, 24, 761–769.
    • (2013) Ann. Oncol , vol.24 , pp. 761-769
    • Abdul Razak, A.R.1    Soulieres, D.2    Laurie, S.A.3    Hotte, S.J.4    Singh, S.5    Winquist, E.6    Chia, S.7    Letourneau, C.8    Nguyen-Tan, P.F.E.X.9
  • 50
    • 84964194350 scopus 로고    scopus 로고
    • Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    • Kim, H.S.; Kwon, H.J.; Jung, I.; Yun, M.R.; Ahn, M.J.; Kang, B.W.; Sun, J.M.; Kim, S.B.; Yoon, D.H.; Park, K.U.; et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin. Cancer Res. 2015, 21, 544–552.
    • (2015) Clin. Cancer Res , vol.21 , pp. 544-552
    • Kim, H.S.1    Kwon, H.J.2    Jung, I.3    Yun, M.R.4    Ahn, M.J.5    Kang, B.W.6    Sun, J.M.7    Kim, S.B.8    Yoon, D.H.K.U.9
  • 51
    • 84933674222 scopus 로고    scopus 로고
    • Targeting angiogenesis in head and neck cancer
    • Vassilakopoulou, M.; Psyrri, A.; Argiris, A. Targeting angiogenesis in head and neck cancer. Oral Oncol. 2015, 51, 409–415.
    • (2015) Oral Oncol , vol.51 , pp. 409-415
    • Vassilakopoulou, M.1    Psyrri, A.2    Argiris, A.3
  • 52
    • 84871554687 scopus 로고    scopus 로고
    • Cetuximab and bevacizumab: Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    • Argiris, A.; Kotsakis, A.P.; Hoang, T.; Worden, F.P.; Savvides, P.; Gibson, M.K.; Gyanchandani, R.; Blumenschein, G.R., Jr.; Chen, H.X.; Grandis, J.R.; et al. Cetuximab and bevacizumab: Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 2013, 24, 220–225.
    • (2013) Ann. Oncol , vol.24 , pp. 220-225
    • Argiris, A.1    Kotsakis, A.P.2    Hoang, T.3    Worden, F.P.4    Savvides, P.5    Gibson, M.K.6    Gyanchandani, R.7    Blumenschein, G.R.8    Chen, H.X.J.R.9
  • 55
    • 77954754601 scopus 로고    scopus 로고
    • Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
    • Williamson, S.K.; Moon, J.; Huang, C.H.; Guaglianone, P.P.; LeBlanc, M.; Wolf, G.T.; Urba, S.G. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J. Clin. Oncol. 2010, 28, 3330–3335.
    • (2010) J. Clin. Oncol , vol.28 , pp. 3330-3335
    • Williamson, S.K.1    Moon, J.2    Huang, C.H.3    Guaglianone, P.P.4    Leblanc, M.5    Wolf, G.T.6    Urba, S.G.7
  • 56
    • 84880049211 scopus 로고    scopus 로고
    • A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
    • Limaye, S.; Riley, S.; Zhao, S.; O'Neill, A.; Posner, M.; Adkins, D.; Jaffa, Z.; Clark, J.; Haddad, R. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013, 49, 835–841.
    • (2013) Oral Oncol , vol.49 , pp. 835-841
    • Limaye, S.1    Riley, S.2    Zhao, S.3    O'neill, A.4    Posner, M.5    Adkins, D.6    Jaffa, Z.7    Clark, J.8    Haddad, R.9
  • 57
    • 84919617522 scopus 로고    scopus 로고
    • Sequencing the head and neck cancer genome: Implications for therapy
    • Sun, W.; Califano, J.A. Sequencing the head and neck cancer genome: Implications for therapy. Ann. N. Y. Acad. Sci.2014, 1333, 33–42.
    • (2014) Ann. N. Y. Acad. Sci , vol.1333 , pp. 33-42
    • Sun, W.1    Califano, J.A.2
  • 58
    • 84933182955 scopus 로고    scopus 로고
    • TEMHEAD: A single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)
    • Grunwald, V.; Keilholz, U.; Boehm, A.; Guntinas-Lichius, O.; Hennemann, B.; Schmoll, H.J.; Ivanyi, P.; Abbas, M.; Lehmann, U.; Koch, A.; et al. TEMHEAD: A single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann. Oncol. 2015, 26, 561–567.
    • (2015) Ann. Oncol , vol.26 , pp. 561-567
    • Grunwald, V.1    Keilholz, U.2    Boehm, A.3    Guntinas-Lichius, O.4    Hennemann, B.5    Schmoll, H.J.6    Ivanyi, P.7    Abbas, M.8    Lehmann, U.A.9
  • 59
    • 84875722517 scopus 로고    scopus 로고
    • A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
    • Bauman, J.E.; Arias-Pulido, H.; Lee, S.J.; Fekrazad, M.H.; Ozawa, H.; Fertig, E.; Howard, J.; Bishop, J.; Wang, H.; Olson, G.T.; et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013, 49, 461–467.
    • (2013) Oral Oncol , vol.49 , pp. 461-467
    • Bauman, J.E.1    Arias-Pulido, H.2    Lee, S.J.3    Fekrazad, M.H.4    Ozawa, H.5    Fertig, E.6    Howard, J.7    Bishop, J.8    Wang, H.G.T.9
  • 60
    • 84946741673 scopus 로고    scopus 로고
    • Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
    • Massarelli, E.; Lin, H.; Ginsberg, L.E.; Tran, H.T.; Lee, J.J.; Canales, J.R.; Williams, M.D.; Blumenschein, G.R., Jr.; Lu, C.; Heymach, J.V.; et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 2015, 26, 1476–1480.
    • (2015) Ann. Oncol , vol.26 , pp. 1476-1480
    • Massarelli, E.1    Lin, H.2    Ginsberg, L.E.3    Tran, H.T.4    Lee, J.J.5    Canales, J.R.6    Williams, M.D.7    Blumenschein, G.R.8    Lu, C.J.V.9
  • 61
    • 84933178034 scopus 로고    scopus 로고
    • A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
    • Jimeno, A.; Bauman, J.E.; Weissman, C.; Adkins, D.; Schnadig, I.; Beauregard, P.; Bowles, D.W.; Spira, A.; Levy, B.; Seetharamu, N.; et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.Oral Oncol. 2015, 51, 383–388.
    • (2015) Oral Oncol , vol.51 , pp. 383-388
    • Jimeno, A.1    Bauman, J.E.2    Weissman, C.3    Adkins, D.4    Schnadig, I.5    Beauregard, P.6    Bowles, D.W.7    Spira, A.8    Levy, B.N.9
  • 62
    • 84933180890 scopus 로고    scopus 로고
    • A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
    • Jimeno, A.; Shirai, K.; Choi, M.; Laskin, J.; Kochenderfer, M.; Spira, A.; Cline-Burkhardt, V.; Winquist, E.; Hausman, D.; Walker, L.; et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.Ann. Oncol. 2015, 26, 556–561.
    • (2015) Ann. Oncol , vol.26 , pp. 556-561
    • Jimeno, A.1    Shirai, K.2    Choi, M.3    Laskin, J.4    Kochenderfer, M.5    Spira, A.6    Cline-Burkhardt, V.7    Winquist, E.8    Hausman, D.L.9
  • 63
    • 79851495693 scopus 로고    scopus 로고
    • Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    • Fury, M.G.; Baxi, S.; Shen, R.; Kelly, K.W.; Lipson, B.L.; Carlson, D.; Stambuk, H.; Haque, S.; Pfister, D.G. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011, 31, 249–253.
    • (2011) Anticancer Res , vol.31 , pp. 249-253
    • Fury, M.G.1    Baxi, S.2    Shen, R.3    Kelly, K.W.4    Lipson, B.L.5    Carlson, D.6    Stambuk, H.7    Haque, S.8    Pfister, D.G.9
  • 65
    • 0034657336 scopus 로고    scopus 로고
    • The role of STATs in transcriptional control and their impact on cellular function
    • Bromberg, J.; Darnell, J.E., Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19, 2468–2473.
    • (2000) Oncogene , vol.19 , pp. 2468-2473
    • Bromberg, J.1    Darnell, J.E.2
  • 66
    • 0034658499 scopus 로고    scopus 로고
    • STAT signaling in head and neck cancer
    • Song, J.I.; Grandis, J.R. STAT signaling in head and neck cancer. Oncogene 2000, 19, 2489–2495.
    • (2000) Oncogene , vol.19 , pp. 2489-2495
    • Song, J.I.1    Grandis, J.R.2
  • 68
    • 84858800620 scopus 로고    scopus 로고
    • The immune contexture in human tumours: Impact on clinical outcome
    • Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298–306.
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 298-306
    • Fridman, W.H.1    Pages, F.2    Sautes-Fridman, C.3    Galon, J.4
  • 69
    • 79959745851 scopus 로고    scopus 로고
    • The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis
    • Gooden, M.J.; de Bock, G.H.; Leffers, N.; Daemen, T.; Nijman, H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br. J. Cancer 2011, 105, 93–103.
    • (2011) Br. J. Cancer , vol.105 , pp. 93-103
    • Gooden, M.J.1    De Bock, G.H.2    Leffers, N.3    Daemen, T.4    Nijman, H.W.5
  • 70
    • 33847190697 scopus 로고    scopus 로고
    • The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas
    • McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J.2006, 26, 154–158.
    • (2006) Iowa Orthop. J , vol.26 , pp. 154-158
    • McCarthy, E.F.1
  • 71
    • 84941060350 scopus 로고    scopus 로고
    • Immunity in head and neck cancer
    • Schoenfeld, J.D. Immunity in head and neck cancer. Cancer Immunol. Res. 2015, 3, 12–17.
    • (2015) Cancer Immunol. Res , vol.3 , pp. 12-17
    • Schoenfeld, J.D.1
  • 72
    • 84948564453 scopus 로고    scopus 로고
    • Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
    • Malm, I.J.; Bruno, T.C.; Fu, J.; Zeng, Q.; Taube, J.M.; Westra, W.; Pardoll, D.; Drake, C.G.; Kim, Y.J. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck 2015, 37, 1088–1095.
    • (2015) Head Neck , vol.37 , pp. 1088-1095
    • Malm, I.J.1    Bruno, T.C.2    Fu, J.3    Zeng, Q.4    Taube, J.M.5    Westra, W.6    Pardoll, D.7    Drake, C.G.8    Kim, Y.J.9
  • 74
    • 46849090082 scopus 로고    scopus 로고
    • Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients
    • Bose, A.; Chakraborty, T.; Chakraborty, K.; Pal, S.; Baral, R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008, 8, 10.
    • (2008) Cancer Immun , vol.8
    • Bose, A.1    Chakraborty, T.2    Chakraborty, K.3    Pal, S.4    Baral, R.5
  • 77
    • 82255179501 scopus 로고    scopus 로고
    • Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
    • Cho, Y.A.; Yoon, H.J.; Lee, J.I.; Hong, S.P.; Hong, S.D. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011, 47, 1148–1153.
    • (2011) Oral Oncol , vol.47 , pp. 1148-1153
    • Cho, Y.A.1    Yoon, H.J.2    Lee, J.I.3    Hong, S.P.4    Hong, S.D.5
  • 79
    • 84879286045 scopus 로고    scopus 로고
    • CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma
    • Nordfors, C.; Grun, N.; Tertipis, N.; Ahrlund-Richter, A.; Haeggblom, L.; Sivars, L.; Du, J.; Nyberg, T.; Marklund, L.; Munck, A; Wikland, E.; et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur. J. Cancer 2013, 49, 2522–2530.
    • (2013) Eur. J. Cancer , vol.49 , pp. 2522-2530
    • Nordfors, C.1    Grun, N.2    Tertipis, N.3    Ahrlund-Richter, A.4    Haeggblom, L.5    Sivars, L.6    Du, J.7    Nyberg, T.8    Marklund, L.A.9    Wikland, E.10
  • 81
    • 70349881470 scopus 로고    scopus 로고
    • Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma
    • Pretscher, D.; Distel, L.V.; Grabenbauer, G.G.; Wittlinger, M.; Buettner, M.; Niedobitek, G. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009, 9, 292.
    • (2009) BMC Cancer , vol.9
    • Pretscher, D.1    Distel, L.V.2    Grabenbauer, G.G.3    Wittlinger, M.4    Buettner, M.5    Niedobitek, G.6
  • 83
    • 84877061277 scopus 로고    scopus 로고
    • B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma
    • Ukpo, O.C.; Thorstad, W.L.; Lewis, J.S., Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2013, 7, 113–121.
    • (2013) Head Neck Pathol , vol.7 , pp. 113-121
    • Ukpo, O.C.1    Thorstad, W.L.2    Lewis, J.S.3
  • 85
    • 84908354848 scopus 로고    scopus 로고
    • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
    • Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W.J.; Gangadhar, T.C.; et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384, 1109–1117.
    • (2014) Lancet , vol.384 , pp. 1109-1117
    • Robert, C.1    Ribas, A.2    Wolchok, J.D.3    Hodi, F.S.4    Hamid, O.5    Kefford, R.6    Weber, J.S.7    Joshua, A.M.8    Hwu, W.J.T.C.9
  • 87
    • 84959392838 scopus 로고    scopus 로고
    • Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients
    • Chicago, IL, USA, 29 May–2 June
    • Seiwert, T.; Burtness, B.; Weiss, J.; Eder, J.P.; Yearley, J.; Murphy, E.; Nebozhyn, M.; McClanahan, T.; Ayers, M.; Lunceford, J.K.; et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. In Proceedings of the 2015 ASCO Annual Meeting, Chicago, IL, USA, 29 May–2 June 2015.
    • (2015) Proceedings of the 2015 ASCO Annual Meeting
    • Seiwert, T.1    Burtness, B.2    Weiss, J.3    Eder, J.P.4    Yearley, J.5    Murphy, E.6    Nebozhyn, M.7    McClanahan, T.8    Ayers, M.J.K.9
  • 90
    • 65549109389 scopus 로고    scopus 로고
    • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years
    • Brown, D.R.; Kjaer, S.K.; Sigurdsson, K.; Iversen, O.-E.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Koutsky, L.A.; Tay, E.H.; Garcia, P.; et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis 2009, 199, 926–935.
    • (2009) J. Infect. Dis , vol.199 , pp. 926-935
    • Brown, D.R.1    Kjaer, S.K.2    Sigurdsson, K.3    Iversen, O.-E.4    Hernandez-Avila, M.5    Wheeler, C.M.6    Perez, G.7    Koutsky, L.A.8    Tay, E.H.P.9
  • 91
    • 0347302952 scopus 로고    scopus 로고
    • Cytokines in cancer pathogenesis and cancer therapy
    • Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4, 11–22.
    • (2004) Nat. Rev. Cancer , vol.4 , pp. 11-22
    • Dranoff, G.1
  • 92
    • 50249168819 scopus 로고    scopus 로고
    • Toll-like receptor modulation in head and neck cancer
    • Pries, R.; Wulff, S.; Wollenberg, B. Toll-like receptor modulation in head and neck cancer. Crit. Rev. Immunol. 2008, 28, 201–213.
    • (2008) Crit. Rev. Immunol , vol.28 , pp. 201-213
    • Pries, R.1    Wulff, S.2    Wollenberg, B.3
  • 93
    • 84919429527 scopus 로고    scopus 로고
    • Toll-like receptors and cancer, particularly oral squamous cell carcinoma
    • Rich, A.M.; Hussaini, H.M.; Parachuru, V.P.; Seymour, G.J. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front. Immunol. 2014, 5, 464.
    • (2014) Front. Immunol , vol.5
    • Rich, A.M.1    Hussaini, H.M.2    Parachuru, V.P.3    Seymour, G.J.4
  • 94
    • 34249677845 scopus 로고    scopus 로고
    • Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
    • Kanzler, H.; Barrat, F.J.; Hessel, E.M.; Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13, 552–559.
    • (2007) Nat. Med , vol.13 , pp. 552-559
    • Kanzler, H.1    Barrat, F.J.2    Hessel, E.M.3    Coffman, R.L.4
  • 97
    • 34249868241 scopus 로고    scopus 로고
    • Adoptive T cell therapy for cancer in the clinic
    • June, C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 2007, 117, 1466–1476.
    • (2007) J. Clin. Invest , vol.117 , pp. 1466-1476
    • June, C.H.1
  • 99
    • 84863269918 scopus 로고    scopus 로고
    • Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy
    • Smith, C.; Tsang, J.; Beagley, L.; Chua, D.; Lee, V.; Li, V.; Moss, D.J.; Coman, W.; Chan, K.H.; Nicholls, J.; et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012, 72, 1116–1125.
    • (2012) Cancer Res , vol.72 , pp. 1116-1125
    • Smith, C.1    Tsang, J.2    Beagley, L.3    Chua, D.4    Lee, V.5    Li, V.6    Moss, D.J.7    Coman, W.8    Chan, K.H.J.9
  • 101
  • 104
    • 0142060273 scopus 로고    scopus 로고
    • Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma
    • Devaraj, K.; Gillison, M.L.; Wu, T.C. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit. Rev. Oral Biol. Med. 2003, 14, 345–362.
    • (2003) Crit. Rev. Oral Biol. Med , vol.14 , pp. 345-362
    • Devaraj, K.1    Gillison, M.L.2    Wu, T.C.3
  • 105
    • 84921710069 scopus 로고    scopus 로고
    • ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen
    • Cory, L.; Chu, C. ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum. Vaccin. Immunother. 2014, 10, 3190–3195.
    • (2014) Hum. Vaccin. Immunother , vol.10 , pp. 3190-3195
    • Cory, L.1    Chu, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.